頁籤選單縮合
題 名 | Venlafaxine與Imipramine治療重度鬱症之比較=Comparison of the Clinical Efficacy and Safety of Venlafaxine and Imipramine in Major Depressive Disorder |
---|---|
作 者 | 葉啟斌; 柯慧貞; 陸汝斌; | 書刊名 | 臺灣精神醫學 |
卷 期 | 13:1 1999.03[民88.03] |
頁 次 | 頁44-53 |
分類號 | 418.214 |
關鍵詞 | 重度鬱症發作; Major depressive disorder; Venlafaxine; Imipramine; |
語 文 | 中文(Chinese) |
中文摘要 | 目的:Venlafaxine為一非三環之抗憂鬱劑,主要藥理作用為同時抑制serotonin 及 norepinephrine 之再吸收 (serotonin and norepinephrine reuptake inhibitor, SNRI)。 故可能產生早期的抗憂鬱效果。 本研究即以 venlafaxine 與傳統三環抗憂鬱劑 imipramine 就兩者對於治療重度鬱症發作之療效、 副作用及安全性做一分析比較。 方法:於某醫院精神部取樣經評估後符合 DSM-IV 重度撬症發作診斷要點,且其漢氏憂鬱量 表 (HAM-D)21 項得分超過 18 分之 71 名患者; 經過隨機分派, 36 名服用 venla- faxine,35 例服用 imipramine,於治療前及治療後之第 0、1、2、3、4、6 過分別以中文 版漢氏憂鬱量表、中文版孟文氏憂鬱量表 (MADRS) 及整體印象評估表 (CGI) 予以評量。 結呆:二組在療效上並未達顯著差異, 而在副作用上如便秘、口乾等, 則 venlafa- xine 組有低於 imipramine 組之傾向。 結論:本研究結果顯示 venlafaxine 組並未較 imipramine 組出現早期發生之療效, 可能 由於未在第二或第二過時加大劑量所致,此有待未來進一步之探討。 |
英文摘要 | Objectives: Venlafaxine hydrochloride, a recently developed compound with a novel structural combination of serotonin and norepinephrine reuptake inhibitors (SNRI), has been reported to have an early onset effect in the treatment of major depressive disorders. This prospective study compared the clinical efficacy, side effects and safety of venlafaxine versus imipramine in the treatment of patients with major depressive disorders. Methods: All patients included in the study met the DSM-IV criteria for a major depressive episode and presented with a total Hamilton De- pression Rating Scale score (18 on the 21-item scale (HAM-D). The study subjects were randomly assigned to venlafaxine or imipramine treatment groups and physicians assessing treatment results were blinded to the group assignment. Depressive symptoms were evaluated by 21-item HAM-D, MADRS (Montgomery, Asberg Depression Rating Scale) and CGI (Clinical Global Impression) weekly in the first 4 weeks and finally in the sixth week. Results: A total of 71 patients who met the inclusion criteria were enrolled in the study. There are no significant differences in efficacy and safety between the two groups; however, fewer side effects were noted in the venlafaxine group. Conclusions: The results of this study are in agreement with those of previous studies with similar design with the exception that venlafaxine was not found to produce earlier-onset efficacy compared to imipramine. ull Text in Chinese) |
本系統中英文摘要資訊取自各篇刊載內容。